SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (651)4/16/1997 11:08:00 AM
From: Vestor   of 1762
 
Reading what you wrote,

> Monoclonal antibody (humanized or prematized) can trigger (in
> repeated treatment) antibody response, which can be accumulative
> during time. This is speculation because there are not enough data
> to oppose or confirm this. Indicative can be marginal side
> effects during clinical trials. Rash, at 140 mg dose, was related,
> according to investigators, to slow absorption of the CE9.1, not to
> antibody/antigen response. But, there are great real risk that
> drugs will not be as effective as in the beginning for the longer
>(several years and longer) therapy-antibody effects.

... If I understand you correctly, you are saying that it is possible,
but unknown yet, whether long-term treatment with the Idec Rheumatoid Arthritis medicine would trigger dangerous antibody response after a time (unknown) that would allow sufficient accumulation.

That would, if it turned out to be the case, probably take their RA medicine off the market .... maybe even before it makes it to market.

This sounds like a highly negative possibility for their RA medicine, which would help explain to me why the stock has dizzily plummeted from 30 to (today) around 17...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News